BOLT · Bolt Biotherapeutics, Inc.
$3.35
+0.14 (+4.36%)
At close · Aug 14
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Under our current operating plans, we believe our cash and cash equivalents and marketable securities of $18.1 million as of June 30, 2026 may be sufficient to fund our operations into first quarter 2027. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 11, 2026
Market Cap
$6.45M
Shares
1.93M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2022-03-30 | — | $75,000,000 | — | 2025-03-29 expired | 10-K , filed 2026-03-12 |